ArticleProceedings of the National Academy of Sciences of the United States of America2017
Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 158 citations in OpenAlex.
- Kupffer cells are key mediators of antigen-specific immune tolerance by peptide-coupled red blood cells.Science advances · 2026Article
- Pharmacokinetics of Ceftriaxone Encapsulated in Carrier Erythrocytes in Experimental Study.Pharmaceutics · 2026Article
- Engineered cell-biomimetic nanosystems for anti-inflammatory therapy: Targeting, neutralization and immunomodulation.Acta pharmaceutica Sinica. B · 2026Review
- Advances of Cell Membrane-Coated Nanotechnology and Membrane Vesicles in Intestinal Targeted Drug Delivery Systems.Pharmaceutics · 2026Review
- A red blood cell-based antigen delivery system to facilitate T cell epitope presentation to promote peripheral tolerance to ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura.Research and practice in thrombosis and haemostasis · 2026Article
- Cell-drug conjugates: a novel drug delivery system for cancer therapy.Theranostics · 2026Review
- Single coadministration of erythrocyte-uricase conjugate and immunosuppressant induces durable immune tolerance for gout therapy.Science advances · 2025Article
- Multiple sclerosis: molecular pathogenesis and therapeutic intervention.Signal transduction and targeted therapy · 2025Review
- Large-Scale Production of Transfusion-Ready Red Blood Cells From Induced Pluripotent Stem Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Targeted Drug Delivery to the Spleen and Its Implications for the Prevention and Treatment of Cancer.Pharmaceutics · 2025Review
- Red blood cells-derived components as biomimetic functional materials: Matching versatile delivery strategies based on structure and function.Bioactive materials · 2025Review
- Strategies to Enhance Protein Delivery.Langmuir : the ACS journal of surfaces and colloids · 2025Review
- Cell-drug conjugates.Nature biomedical engineering · 2024Review
- Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders.Signal transduction and targeted therapy · 2024Review
- Developing an erythrocyte‒MHC-I conjugate for cancer treatment.Cell discovery · 2024Article
- Lymphoid organ-targeted nanomaterials for immunomodulation of cancer, inflammation, and beyond.Chemical Society reviews · 2024Review
- Building Synthetic Biosensors Using Red Blood Cell Proteins.ACS synthetic biology · 2024Article
- Red blood cell-derived materials for cancer therapy: Construction, distribution, and applications.Materials today. Bio · 2024Review
- Red blood cells in biology and translational medicine: natural vehicle inspires new biomedical applications.Theranostics · 2024Review
- Antigen-specific T cell responses in autoimmune diabetes.Frontiers in immunology · 2024Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issuedCorrection for Pishesha et al., Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease.2017 · Dhesycka, Rhogerry [corrected to Deshycka, Rhogerry]
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
Current therapies for autoimmune diseases rely on traditional immunosuppressive medications that expose patients to an increased risk of opportunistic infections and other complications. Immunoregulatory interventions that act prophylactically or therapeutically to induce antigen-specific tolerance might overcome these obstacles. Here we use the transpeptidase sortase to covalently attach disease-associated autoantigens to genetically engineered and to unmodified red blood cells as a means of inducing antigen-specific tolerance. This approach blunts the contribution to immunity of major subsets of immune effector cells (B cells, CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.